Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Nanomedicine and immunotherapy : a step further towards precision medicine for glioblastoma
ID
Šamec, Neja
(
Avtor
),
ID
Zottel, Alja
(
Avtor
),
ID
Videtič Paska, Alja
(
Avtor
),
ID
Jovchevska, Ivana
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(1,18 MB)
MD5: A8EEDC0CE330B7D661E75D9FE7B5CD48
URL - Izvorni URL, za dostop obiščite
https://www.mdpi.com/1420-3049/25/3/490
Galerija slik
Izvleček
Owing to the advancement of technology combined with our deeper knowledge of human nature and diseases, we are able to move towards precision medicine, where patients are treated at the individual level in concordance with their genetic profiles. Lately, the integration of nanoparticles in biotechnology and their applications in medicine has allowed us to diagnose and treat disease better and more precisely. As a model disease, we used a grade IV malignant brain tumor (glioblastoma). Significant improvements in diagnosis were achieved with the application of fluorescent nanoparticles for intraoperative magnetic resonance imaging (MRI), allowing for improved tumor cell visibility and increasing the extent of the surgical resection, leading to better patient response. Fluorescent probes can be engineered to be activated through different molecular pathways, which will open the path to individualized glioblastoma diagnosis, monitoring, and treatment. Nanoparticles are also extensively studied as nanovehicles for targeted delivery and more controlled medication release, and some nanomedicines are already in early phases of clinical trials. Moreover, sampling biological fluids will give new insights into glioblastoma pathogenesis due to the presence of extracellular vesicles, circulating tumor cells, and circulating tumor DNA. As current glioblastoma therapy does not provide good quality of life for patients, other approaches such as immunotherapy are explored. To conclude, we reason that development of personalized therapies based on a patient’s genetic signature combined with pharmacogenomics and immunogenomic information will significantly change the outcome of glioblastoma patients.
Jezik:
Angleški jezik
Ključne besede:
glioblastoma
,
extracellular vesicles
,
nanoscience
,
cell free DNA
,
circulating tumor DNA
,
liquid biopsy
,
immunotherapy
Vrsta gradiva:
Članek v reviji
Tipologija:
1.02 - Pregledni znanstveni članek
Organizacija:
MF - Medicinska fakulteta
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2020
Št. strani:
33 str.
Številčenje:
Vol. 25, iss. 3, art. 490
PID:
20.500.12556/RUL-133241
UDK:
577
ISSN pri članku:
1420-3049
DOI:
10.3390/molecules25030490
COBISS.SI-ID:
34662361
Datum objave v RUL:
18.11.2021
Število ogledov:
2080
Število prenosov:
164
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Molecules
Skrajšan naslov:
Molecules
Založnik:
MDPI
ISSN:
1420-3049
COBISS.SI-ID:
18462981
Licence
Licenca:
CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:
To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:
01.02.2020
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
glioblastom
,
zunajcelični vezikli
,
nanoznanost
Projekti
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P1-0390
Naslov:
Funkcijska genomika in biotehnologija za zdravje
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Program financ.:
Young Researcher Grant
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
Z3-1869
Naslov:
Razvoj anti-FREM2 nanotelesa in njegova uporaba pri ciljanju glioblastomskih celic
Financer:
EC - European Commission
Program financ.:
Interreg
Številka projekta:
146
Akronim:
TRANS-GLIOMA
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj